For example, MT2A is upregulated in osteosarcoma, breast cancer and prostate cancer [17–19], with carcinogenic roles, while it is downregulated in gastric carcinoma, hepatoma and lung cancer [20–22], with cancer suppression roles. Here, MT2A is linked to prostate carcinoma.